Goldenberg MM (2012) Multiple sclerosis review. P T 37:175–184

PubMed  PubMed Central  Google Scholar 

Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5:343–354

Article  Google Scholar 

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stuve O, Waubant E, Polman CH (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278–286

Article  Google Scholar 

Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129:584–594

CAS  Article  Google Scholar 

Larochelle C, Uphaus T, Prat A, Zipp F (2016) Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology? Trends Neurosci 39:325–339

CAS  Article  Google Scholar 

Matias-Guiu JA, Cortés-Martínez A, Valles-Salgado M, Oreja-Guevara C, Pytel V, Montero P, Moreno-Ramos T, Matias-Guiu J (2017) Functional components of cognitive impairment in multiple sclerosis: a cross-sectional investigation. Front Neurol 8:643

Article  Google Scholar 

Ruano L, Portaccio E, Goretti B, Niccolai C, Severo M, Patti F, Cilia S, Gallo P, Grossi P, Ghezzi A, Roscio M, Mattioli F, Stampatori C, Trojano M, Viterbo RG, Amato MP (2017) Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler 23:1258–1267

Article  Google Scholar 

Planche V, Gibelin M, Cregut D, Pereira B, Clavelou P (2016) Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol 23:282–289

CAS  Article  Google Scholar 

Costa SL, Genova HM, DeLuca J, Chiaravalloti ND (2017) Information processing speed in multiple sclerosis: past, present, and future. Mult Scler 23:772–789

Article  Google Scholar 

Carotenuto A, Moccia M, Costabile T, Signoriello E, Paolicelli D, Simone M, Lus G, Brescia Morra V, Lanzillo R (2019) Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis. Sci Rep 9:18074

CAS  Article  Google Scholar 

Pitteri M, Romualdi C, Magliozzi R, Monaco S, Calabrese M (2017) Cognitive impairment predicts disability progression and cortical thinning in MS: an 8-year study. Mult Scler 23:848–854

Article  Google Scholar 

Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712

Article  Google Scholar 

Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallstrom E (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 167:1035–1047

CAS  Article  Google Scholar 

Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355–360

CAS  Article  Google Scholar 

Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, Walsh FS, Pangalos MN, Arimura N, Kaibuchi K, Zalc B, Lubetzki C (2005) Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 25:1459–1469

CAS  Article  Google Scholar 

Mannioui A, Vauzanges Q, Fini JB, Henriet E, Sekizar S, Azoyan L, Thomas JL, Pasquier DD, Giovannangeli C, Demeneix B, Lubetzki C, Zalc B (2018) The XenopuIs tadpole: an in vivo model to screen drugs favoring remyelination. Mult Scler 24:1421–1432

CAS  Article  Google Scholar 

O’Sullivan C, Schubart A, Mir AK, Dev KK (2016) The dual S1PR1/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation 13:31

Article  Google Scholar 

Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, Piras E, Gargano F, Borsellino G, Battistini L, Schubart A, Mandolesi G, Centonze D (2016) Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation 13:207

Article  Google Scholar 

Bigaud M, Rudolph B, Briard E, Beerli C, Hofmann A, Hermes E, Muellershausen F, Schubart A, Gardin A (2021) Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: preclinical insights. Mult Scler J Exp Transl Clin 7:20552173211049170

PubMed  Google Scholar 

Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Wright I, Karlsson G, Dahlke F, Wolf C, Kappos L (2020) Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses. Neurology 96:e376–e386

Article  Google Scholar 

European Medicines Agency (2020) Mayzent summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf Accessed 23 May 2020.

Arnold DL, Fox R, Bar-Or A, et al (2019) Effect of siponimod on cortical grey matter and thalamic volume in patients with secondary progressive multiple sclerosis – results of the EXPAND study. In: 35th ECTRIMS Congress; 11–13 September 2019; Stockholm, Sweden, P382

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallstrom E, Dahlke F, Investigators EC (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391:1263–1273

CAS  Article  Google Scholar 

Novartis Pharmaceuticals Australia Pty Limited (2019) Australian Product Information - Mayzent (siponimod) tablets. https://www.tga.gov.au/sites/default/files/auspar-siponimod-191211-pi.pdf Accessed 12 January 2020.

Food and Drug Administration (2020) Mayzent prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf Accessed 22 January 2020.

World Medical Association (2020) WMA Declaration of Helsinki—ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ Accessed 1 July 2020.

Smith A (1982) Symbol digit modalities test: manual. Western Psychological Services, Los Angeles

Google Scholar 

Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R, Multiple Sclerosis Outcome Assessments C (2017) Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 23:721–733

Article  Google Scholar 

Benedict RHB, Amato MP, DeLuca J, Geurts JJG (2020) Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol 19:860–871

Article  Google Scholar 

Penner IK, Giovannoni G, Cree B, et al (2020) Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease. In: MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting; 11–13 September 2020; Virtual, P0806

Ksiazek-Winiarek DJ, Szpakowski P, Glabinski A (2015) Neural plasticity in multiple sclerosis: the functional and molecular background. Neural Plast 2015:307175

Article  Google Scholar 

Arnold DL, Piani-Meier D, Bar-Or A, Benedict RH, Cree BA, Giovannoni G, Gold R, Vermersch P, Arnould S, Dahlke F, Hach T, Ritter S, Karlsson G, Kappos L, Fox RJ, Investigators EC (2022) Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Mult Scler. https://doi.org/10.1177/13524585221076717

Article  PubMed  PubMed Central  Google Scholar 

Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D, Rouyrre N, Ritter S, Kilaru A, Karlsson G, Giovannoni G, Kappos L (2022) Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: analysis of EXPAND core and extension data up to >5 years. Mult Scler. https://doi.org/10.1177/13524585221083194

Article  PubMed  PubMed Central  Google Scholar 

Cree BA, Magnusson B, Rouyrre N, Fox RJ, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Piani Meier D, Karlsson G, Tomic D, Wolf C, Dahlke F, Siponimod KL (2022) Disentangling disability and relapses in secondary progressive multiple sclerosis. Mult Scler J. https://doi.org/10.1177/1352458520971819

Article  Google Scholar 

Dahlke F, Arnold DL, Aarden P, Ganjgahi H, Haring DA, Cuklina J, Nichols TE, Gardiner S, Bermel R, Wiendl H (2021) Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): age is a key contributor to presentation. Mult Scler 27:2062–2076

CAS  Article  Google Scholar